Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | WDR5 | P61964 | 12/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835859 | 0.88 | MAPT (0.70) | ALDH1A1KMT2AMAPTWDR5GAA | |
| SCHEMBL282334 | 0.86 | WDR5 (0.73) | ALDH1A1WDR5GAACYP2D6HTT | |
| SCHEMBL30879000 | 0.86 | WDR5 (0.73) | ALDH1A1WDR5GAACYP2D6HTT | |
| SCHEMBL8992892 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTWDR5GAA | |
| SCHEMBL1841763 | 0.79 | TDP1 (0.68) | ALDH1A1KMT2AMAPTWDR5GAA | |
| SCHEMBL10126930 | 0.78 | WDR5 (0.61) | ALDH1A1KMT2AWDR5GAACYP2D6 | |
| SCHEMBL10126926 | 0.77 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTGAACYP2D6 | |
| SCHEMBL24900638 | 0.77 | WDR5 (0.74) | ALDH1A1KMT2AMAPTWDR5GAA | |
| SCHEMBL29228991 | 0.77 | WDR5 (0.74) | ALDH1A1KMT2AMAPTWDR5GAA | |
| SCHEMBL29229226 | 0.77 | WDR5 (0.74) | ALDH1A1KMT2AMAPTWDR5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALDH1A1 1554/4885KMT2A 103/4885MAPT 3116/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALDH1A1 1554/4885KMT2A 103/4885MAPT 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.